Sutro Biopharma presents innovative antibody drug conjugate data at the 16th Annual World ADC Conference in San Diego.
Quiver AI Summary
Sutro Biopharma, Inc. announced its participation in the 16th Annual World ADC Conference in San Diego from November 3-6, 2025, where it will present new preclinical data highlighting advancements in its innovative antibody-drug conjugate (ADC) platform. Chief Scientific Officer Hans-Peter Gerber emphasized the significance of their dual-payload ADCs and immunostimulatory ADCs in improving therapeutic outcomes and addressing challenges such as tumor resistance in oncology. The company will showcase multiple presentations led by its scientists, discussing the development and advantages of site-specific, high-DAR dual-payload ADCs and the unique benefits of its cell-free manufacturing platform. Sutro aims to enhance cancer treatment options through its next-generation ADCs and plans to make presentation content available on its website following the event.
Potential Positives
- Participation at the prestigious 16th Annual World ADC Conference highlights Sutro Biopharma's commitment to industry engagement and thought leadership in oncology.
- Presentation of new preclinical data on dual-payload ADCs could position Sutro as an innovator capable of addressing significant challenges in cancer treatment, such as tumor resistance.
- Unique cell-free platform showcased may reinforce Sutro's competitive advantage in the design and production of advanced ADCs, potentially attracting investor interest and partnerships.
- The focus on next-generation therapies emphasizes Sutro's ambition to transform cancer care, aligning with the growing demand for innovative treatment options in the oncology market.
Potential Negatives
- The company highlights the potential benefits of its products without providing concrete evidence or data, which may raise skepticism among investors and industry experts regarding the validity of its claims.
- Forward-looking statements include numerous risks and uncertainties, indicating that achieving anticipated development milestones is not guaranteed, which may concern stakeholders.
- There is no mention of any current partnerships or collaborations that could provide validation or additional resources for their ADC platform, potentially signaling a lack of support in a competitive market.
FAQ
What is Sutro Biopharma presenting at the World ADC Conference?
Sutro Biopharma is presenting new preclinical data showcasing innovations in antibody drug conjugates (ADCs).
When is the World ADC Conference taking place?
The World ADC Conference is happening from November 3-6, 2025, in San Diego.
Who are the key presenters from Sutro Biopharma?
Key presenters include Dr. Hans-Peter Gerber, Dr. Daniel Calarese, and Dr. Gang Yin.
What innovations are highlighted by Sutro's ADCs?
Sutro's ADCs focus on dual-payload formulations that enhance therapeutic index and tackle tumor resistance.
Where can I find more information after the conference?
Content from the conference will be available on Sutro Biopharma's website in the Clinical/Scientific Presentation section.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$STRO Insider Trading Activity
$STRO insiders have traded $STRO stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $STRO stock by insiders over the last 6 months:
- CONNIE MATSUI purchased 50,000 shares for an estimated $39,950
- GREGORY K. CHOW (CFO) purchased 19,750 shares for an estimated $15,997
- HANS-PETER GERBER (CHIEF SCIENTIFIC OFFICER) purchased 17,000 shares for an estimated $13,606
- JANE CHUNG (Chief Executive Officer) purchased 12,500 shares for an estimated $10,011
- DAVID PAULING (Chief Admin. Ofcr. & GC) purchased 12,504 shares for an estimated $9,993
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$STRO Hedge Fund Activity
We have seen 45 institutional investors add shares of $STRO stock to their portfolio, and 74 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. removed 4,434,637 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $3,165,887
- BLACKROCK, INC. removed 4,097,776 shares (-66.0%) from their portfolio in Q2 2025, for an estimated $2,925,402
- MILLENNIUM MANAGEMENT LLC added 4,029,088 shares (+573.0%) to their portfolio in Q2 2025, for an estimated $2,876,365
- TANG CAPITAL MANAGEMENT LLC added 2,361,586 shares (+1180.8%) to their portfolio in Q2 2025, for an estimated $1,685,936
- VELAN CAPITAL INVESTMENT MANAGEMENT LP added 2,030,000 shares (+197.1%) to their portfolio in Q2 2025, for an estimated $1,449,217
- UBS GROUP AG added 1,543,313 shares (+2042.2%) to their portfolio in Q2 2025, for an estimated $1,101,771
- STATE STREET CORP removed 1,339,687 shares (-79.6%) from their portfolio in Q2 2025, for an estimated $956,402
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$STRO Analyst Ratings
Wall Street analysts have issued reports on $STRO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 06/16/2025
- B of A Securities issued a "Underperform" rating on 05/19/2025
To track analyst ratings and price targets for $STRO, check out Quiver Quantitative's $STRO forecast page.
$STRO Price Targets
Multiple analysts have issued price targets for $STRO recently. We have seen 3 analysts offer price targets for $STRO in the last 6 months, with a median target of $2.0.
Here are some recent targets:
- Derek Archila from Wells Fargo set a target price of $3.0 on 08/12/2025
- Edward Tenthoff from Piper Sandler set a target price of $2.0 on 06/16/2025
- Tazeen Ahmad from B of A Securities set a target price of $0.8 on 05/19/2025
Full Release
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 16th Annual World ADC Conference, taking place in San Diego, November 3-6, 2025.
“We look forward to presenting new preclinical data at this year’s World ADC conference that underscore the breadth of innovation emerging from Sutro’s platform and the meaningful progress we’re making toward advancing the next-generation of ADCs,” said Hans-Peter Gerber, Sutro’s Chief Scientific Officer. “Among the highlights, we’re excited to share results demonstrating how our dual-payload ADCs, including immunostimulatory ADCs, can potentially redefine treatment paradigms by enhancing therapeutic index and addressing tumor resistance—two of the biggest challenges in oncology today. Together with our unique cell-free platform, these advances reinforce Sutro’s leadership in ADC innovation and our commitment to driving long-term value through transformative science.”
Presentation/Panel Discussion Details:
-
Showcasing Development of Site-Specific, High-DAR Dual-Payload ADCs
- Presenter: Daniel Calerese, Ph.D.
-
Date/Time: November 3, 2025, 12:00PM PT
-
Developing Next-Generation Immunostimulatory Dual Payload ADCs to Enhance Therapeutic Index & Tackle Patient Resistance
- Presenter: Gang Yin, Ph.D.
-
Date/Time: November 3, 2025, 12:30PM PT
-
Exploring Supply Chain & CMC Advantages of Cell-Free Antibody Manufacturing to Design & Produce Unique ADCs
- Presenter: Venkatesh Srinivasan, Ph.D.
-
Date/Time: November 4, 2025, 11:00AM PT
-
Panel Discussion: Delving into Novel Design & Development to Strive for Next-Generation ADCs Providing Long-Term Benefit to Patients
- Sutro Participant: Hans-Peter Gerber, Ph.D.
-
Date/Time: November 4, 2025, 5:00PM PT
-
Developing Site-Specific Dual Payload ADCs Featuring Novel Linker Payloads to Overcome Resistance Mechanisms
- Presenter: Krishna Bajjuri, Ph.D.
-
Date/Time: November 5, 2025, 11:00AM PT
-
Panel Discussion: The Way Forward: What’s the New Path to the Next-Generation of ADCs?
- Sutro Participant: Daniel Calarese, Ph.D.
-
Date/Time: November 5, 2025, 12:30PM PT
-
Laying Out Discovery & Development of STRO-006: A Differentiated Topo1-ADC Targeting Integrin Beta-6
- Presenter: Alice Yam, Ph.D.
-
Date/Time: November 5, 2025, 2:00PM PT
-
Summary Panel Discussion: What is Showing the Most Promise & What Still Needs to be Proven in ADC Chemistry Innovation?
- Sutro Participant: Hans-Peter Gerber, Ph.D.
-
Date/Time: November 5, 2025, 3:00PM PT
Following the event, the content will be made available in the Clinical/Scientific Presentation and Publication Highlights section of Sutro Biopharma’s website at www.sutrobio.com .
About Sutro Biopharma
Sutro Biopharma, Inc. is advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies.
For more information, follow Sutro on social media @Sutrobio or visit www.sutrobio.com .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated preclinical and clinical development activities; timing of announcements of IND submissions, clinical results, trial initiation, and other regulatory filings; outcome of discussions with regulatory authorities; potential benefits of the Company’s product candidates and platform; and potential market opportunities for the Company’s product candidates; . All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the Company’s ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, the market size for the Company’s product candidates to be smaller than anticipated, clinical trial sites, supply chain and manufacturing facilities, the Company’s ability to obtain, maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, the Company’s ability to fund development activities and achieve development goals, the Company’s ability to protect intellectual property, and the Company’s commercial collaborations with third parties and other risks and uncertainties described under the heading “Risk Factors” in documents the Company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
